Clinical Trial Update: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating risk-stratified sequential treatment of post-transplant lymphoproliferative disorder using rituximab subcutaneous administrati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttransplant Lymphoproliferative Disorder

Drugs mentioned

• rituximab SC (rituximab)

Snippet

Sponsor: Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH | Conditions: Posttransplant Lymphoproliferative Disorder | Phase 2 | Status: COMPLETED